MX2023003576A - Compuesto como inhibidor de la akt cinasa. - Google Patents

Compuesto como inhibidor de la akt cinasa.

Info

Publication number
MX2023003576A
MX2023003576A MX2023003576A MX2023003576A MX2023003576A MX 2023003576 A MX2023003576 A MX 2023003576A MX 2023003576 A MX2023003576 A MX 2023003576A MX 2023003576 A MX2023003576 A MX 2023003576A MX 2023003576 A MX2023003576 A MX 2023003576A
Authority
MX
Mexico
Prior art keywords
compound
akt kinase
kinase inhibitor
preparation
drug
Prior art date
Application number
MX2023003576A
Other languages
English (en)
Inventor
Yong Gao
Wei Shi
Damin Zhao
Yuan Yin
Yinsheng Zhang
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of MX2023003576A publication Critical patent/MX2023003576A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0816—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring comprising Si as a ring atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se proporciona un compuesto como un inhibidor de Akt cinasa. La presente invención se refiere específicamente a un compuesto de fórmula (I) o a una sal farmacéuticamente aceptable del mismo, a un método de preparación del mismo, a una composición farmacéutica que contiene el compuesto y al uso del mismo en la preparación de un fármaco para tratar enfermedades relacionadas con Akt cinasa. (ver Fórmula).
MX2023003576A 2020-09-30 2021-09-30 Compuesto como inhibidor de la akt cinasa. MX2023003576A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202011057860 2020-09-30
CN202110261605 2021-03-10
PCT/CN2021/122040 WO2022068917A1 (zh) 2020-09-30 2021-09-30 作为Akt激酶抑制剂的化合物

Publications (1)

Publication Number Publication Date
MX2023003576A true MX2023003576A (es) 2023-04-04

Family

ID=80951238

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003576A MX2023003576A (es) 2020-09-30 2021-09-30 Compuesto como inhibidor de la akt cinasa.

Country Status (11)

Country Link
US (1) US20230357242A1 (es)
EP (1) EP4223754A4 (es)
JP (1) JP2023542969A (es)
KR (1) KR20230079113A (es)
CN (2) CN117486876A (es)
AU (1) AU2021351093A1 (es)
CA (1) CA3193341A1 (es)
IL (1) IL301567A (es)
MX (1) MX2023003576A (es)
TW (1) TW202214631A (es)
WO (1) WO2022068917A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024010784A1 (en) * 2022-07-06 2024-01-11 Vividion Therapeutics, Inc. Pharmaceutical compositions comprising wrn helicase inhibitors
WO2024102621A1 (en) * 2022-11-09 2024-05-16 Alterome Therapeutics, Inc. Akt1 modulators
WO2024178390A1 (en) * 2023-02-24 2024-08-29 Terremoto Biosciences, Inc. Covalent modifiers of akt1 and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG181947A1 (en) * 2009-12-30 2012-07-30 Arqule Inc Substituted imidazopyridinyl-aminopyridine compounds
US8815854B2 (en) * 2011-06-24 2014-08-26 Arqule, Inc. Substituted imidazopyridinyl compounds
CA2837727C (en) * 2011-06-24 2019-12-03 Arqule, Inc. Substituted imidazopyridinyl-aminopyridine compounds
ES2955926T3 (es) * 2014-09-05 2023-12-11 Arqule Inc Composiciones y métodos para tratar trastornos proliferativos

Also Published As

Publication number Publication date
AU2021351093A9 (en) 2024-09-12
TW202214631A (zh) 2022-04-16
JP2023542969A (ja) 2023-10-12
CA3193341A1 (en) 2022-04-07
CN117486876A (zh) 2024-02-02
WO2022068917A1 (zh) 2022-04-07
EP4223754A4 (en) 2024-10-02
AU2021351093A1 (en) 2023-06-01
EP4223754A1 (en) 2023-08-09
US20230357242A1 (en) 2023-11-09
KR20230079113A (ko) 2023-06-05
IL301567A (en) 2023-05-01
CN116194452A (zh) 2023-05-30

Similar Documents

Publication Publication Date Title
MX2023007192A (es) Inhibidores de prmt5.
MX2022010011A (es) Inhibidores de prmt5 novedosos.
MX2023003576A (es) Compuesto como inhibidor de la akt cinasa.
MX2022008881A (es) Compuesto heterociclico de pirimidin-4(3h)-ona, metodo de preparacion del mismo y su uso farmaceutico.
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
MX2023015533A (es) Compuesto tetraciclico fusionado, metodo de preparacion y aplicacion en medicina.
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
GB0112348D0 (en) Compounds
MX2023007853A (es) Compuesto heterociclico puenteado que contiene nitrogeno, metodo de preparacion y uso medico del mismo.
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
MX2022015531A (es) Derivado de piridina-pirimidina, metodo de preparacion y uso farmaceutico del mismo.
MX2022005985A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
MX2023013890A (es) Compuesto heterociclico que contiene nitrogeno, metodo de preparacion del mismo y aplicacion del mismo en medicamentos.
MX2022015554A (es) Moduladores de molecula peque?a de interleucina 17 (il-17).
PH12021551057A1 (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
MX2021013576A (es) Compuesto utilizado como inhibidor de la quinasa y aplicación del mismo.
MX2023006504A (es) Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo.
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
MX2022013273A (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus metodos de uso.
MX2024004846A (es) Compuesto tetraciclico que contiene nitrogeno, metodo de preparacion del mismo y uso medico del mismo.
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof
MX2021013942A (es) Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton.
MX2024000999A (es) Antagonista de molécula pequeña de lpa1.